Time to recovery of Sp02;Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis;Number of Participants with Changes to overall assessment of Electrocardiogram;Incidence of Treatment-Emergent Serious Adverse Events;Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.;Number of Participants with Changes in Echocardiography Overall Assessment;Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.;Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.

Time to recovery of Sp02;Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis;Number of Participants with Changes to overall assessment of Electrocardiogram;Incidence of Treatment-Emergent Serious Adverse Events;Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.;Number of Participants with Changes in Echocardiography Overall Assessment;Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.;Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.